Tekin H, Simmons S, Cummings B, et al. Effects of 3D culturing conditions on the transcriptomic profile of stem-cell-derived neurons. Nat Biomed Eng. 2018;2:540–554.
Shalek AK, Satija R, Adiconis X, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature. 2013;498:236–240.
Levin JZ, Yassour M, Adiconis X, et al. Comprehensive comparative analysis of strand-specific RNA sequencing methods. Nat Methods. 2010;7:709–715.
Joshua Levin, Ph.D.
Joshua Levin is a senior group leader and research scientist in the Broad Institute of MIT and Harvard’s Stanley Center for Psychiatric Research, as well as in the Klarman Cell Observatory. In his research, he uses transcriptomic approaches to improve our understanding of brain function as it relates to psychiatric disorders such as autism and schizophrenia. During his time at the Broad Institute, he has developed and comprehensively evaluated an extensive portfolio of RNA sequencing (RNA-Seq) methods such as targeted, strand-specific, total, and low-input RNA-Seq protocols. These RNA-Seq methodologies are being used for a variety of projects institute-wide, notably cancer transcriptomics, single cell studies, and genome annotation. Levin has also established next-generation sequencing methods for RNA viruses including HIV, West Nile virus, and Lassa virus.
Before joining the Broad Institute in 2007, Levin worked for ten years in the biotechnology industry, first at Syngenta (formerly Ciba-Geigy and Novartis) and later at Novartis Pharmaceuticals using model organisms in functional genomics studies.
Levin received his B.A. in biochemistry from the University of Pennsylvania and his Ph.D. in biology from MIT in the laboratory of Robert Horvitz. His postdoctoral studies were undertaken at the California Institute of Technology, where he investigated genetic and molecular factors affecting flower development in Arabidopsis.